Background
Methods
Literature review
Search strategy
Study selection
Data extraction process
Statistical analysis
Results
Literature review
Regression analysis
Relationships with exacerbations at ≥48 weeks
Forced Expiratory Volume in One Second (trough FEV1)
Author, Year | Treatment | Time point (weeks) | N Randomized | Definition of exacerbation | Annual exacerbation rate | N with any exacerbation | Comparison data for Time to first exacerbation (Hazard ratio) | Mean change in Trough FEV1 (L) | Comparison data for Trough FEV1 (treatment difference) |
---|---|---|---|---|---|---|---|---|---|
Bateman, 2010 [10] | Tiotropium 5 ug | 48 | 1989 | B+ | 0.12 | 685 | Tio5 vs. Placebo: 0.69 | 0.119 | -- |
Placebo | 48 | 2002 | 0.15 | 842 | 0.018 | -- | |||
Calverley, 2010 [12] | Beclomethasone/formoterol pMDI 400/24 μg | 48 | 237 | NR | 0.074 | 64 | -- | 0.077 | B/F pMDI vs. F-DPI: 0.051 |
Budesonide/formoterol DPI)800/24 μg | 48 | 242 | 0.033 | 64 | -- | 0.08 | B/F dry vs. F-DPI: 0.053 | ||
Formoterol DPI 12 μg | 48 | 239 | 0.04 | 66 | -- | 0.026 | -- | ||
Chapman, 2011 [13] | Indacaterol, 150 μg | 52 | 420 | A | -- | -- | Ind150 vs. Placebo: 0.82 | 0.12 | -- |
Indacaterol, 300 μg | 52 | 418 | -- | -- | Ind300 vs. Placebo: 0.86 | 0.13 | -- | ||
Placebo | 52 | 425 | -- | -- | -0.04 | -- | |||
Dahl, 2010 [14] | Indacaterol 300 μg | 52 | 437 | A | -- | -- | Inda300 vs. Placebo: 0.77 | -- | Inda300 vs. Placebo: 0.16 |
Indacaterol 600 μg | 52 | 428 | -- | -- | Inda600 vs. Placebo: 0.69 | -- | Inda600 vs. Placebo: 0.15 | ||
Formoterol | 52 | 435 | -- | -- | F vs. Placebo: 0.77 | -- | F vs. Placebo: 0.05 | ||
Placebo | 52 | 432 | -- | -- | -- | -- | |||
Decramer, 2013 [15] | Tiotropium bromide 18 μg | 26 | 1721 | C | -- | -- | Tio18 vs. Inda150: 0.81 | -- | Tio18 vs. Inda150: 0.02 |
Indacaterol maleate 150 μg once-daily | 26 | 1723 | -- | -- | -- | -- | |||
Tiotropium bromide 18 μg | 52 | 1721 | 0.07 | 547 | -- | 0.092 | -- | ||
Indacaterol maleate 150 μg once-daily | 52 | 1723 | 0.1 | 619 | -- | 0.073 | -- | ||
Dusser, 2006 [16] | Tiotropium 18 μg once daily | 48 | 500 | C | -- | 248 | -- | -- | -- |
Placebo | 48 | 510 | -- | 305 | -- | -- | Tio18 vs. Placebo: 0.12 | ||
Ferguson, 2008 [17] | Fluticasone propionate/salmeterol (FSC) 250/50 | 52 | 394 | C | -- | 343 | -- | -0.012 | -- |
Salmeterol 50 μg | 52 | 388 | -- | 335 | -- | -0.082 | -- | ||
van Grunsven, 2003 [18] | Fluticasone propionate (Flixotides) 250 μg bid | 103 | 24 | D | -- | 5 | -- | -0.12 | F250 vs. Placebo: 0.06 |
Placebo bid | 103 | 24 | -- | 3 | -- | -0.17 | -- | ||
Vincken, 2002 [19] | Tiotropium 18 μg qd in the morning | 52 | 356 | B | -- | 125 | -- | 0.12 | -- |
Ipratropium 40 μg qid | 52 | 179 | -- | 82 | -- | -0.03 | -- | ||
Wouters, 2005 [20] | Salmeterol/fluticasone (3 month run in period of salmeterol 50 μg and fluticasone 500 μg bid) | 52 | 189 | E | -- | 115 | -- | -0.04 | S/F vs. S: 0.05 |
Salmeterol (3 month run in period of salmeterol 50 μg and fluticasone 500 μg bid) | 52 | 184 | -- | 109 | -- | -0.1 | -- | ||
Zhou, 2006 [21] | Theophylline | 52 | 57 | C | -- | 26 | -- | 0.0063 | -- |
Placebo | 52 | 53 | -- | 30 | -- | -0.0533 | -- | ||
Dransfield, 2013 [22] | Vilanterol 25 μg | 52 | 409 | A | -- | 203 | -- | -0.04 | -- |
Fluticasone furoate 50 μg + Vilanterol 25 μg | 52 | 408 | -- | 190 | -- | 0 | -- | ||
Fluticasone furoate 100 μg + Vilanterol 25 μg | 52 | 403 | -- | 161 | -- | 0.02 | -- | ||
Fluticasone furoate 200 μg + Vilanterol 25 μg | 52 | 402 | -- | 178 | -- | 0.02 | -- | ||
Vilanterol 25 μg | 52 | 409 | -- | 197 | -- | -0.02 | -- | ||
Fluticasone furoate 50 μg + Vilanterol 25 μg | 52 | 412 | -- | 198 | -- | 0.02 | -- | ||
Fluticasone furoate 100 μg + Vilanterol 25 μg | 52 | 403 | -- | 177 | -- | 0.01 | -- | ||
Fluticasone furoate 200 μg + Vilanterol 25 μg | 52 | 409 | -- | 160 | -- | 0.01 | -- |
Author, Year | Treatment | Time point (weeks) | N Randomized | Annual exacerbation rate (M-S) | N with M-S exacerbation | Comparison data for Time to first exacerbation (Hazard ratio) | Mean change in Trough FEV1 (L) | Comparison data for Trough FEV1 (treatment difference) |
---|---|---|---|---|---|---|---|---|
Anzueto, 2009 [23] | Fluticasone propionate/salmeterol 250 mcg/50 mcg bid | 52 | 394 | 1.1 | 208 | FP250 + S50 vs. S50: 0.73 | -0.017 | -- |
Salmeterol 50 mcg bid | 52 | 403 | 1.59 | 234 | -- | -0.097 | -- | |
Bateman, 2010 [10] | Tiotropium 5 μg orally inhaled once daily | 48 | 670 | 0.93 | 249 | -- | 0.08 | Tio5 vs. Placebo: 0.127 |
Tiotropium 10 μg orally inhaled once daily | 48 | 667 | 1.02 | 246 | -- | 0.11 | Tio10 vs. Placebo: 0.150 | |
Placebo | 48 | 653 | 1.91 | 288 | -- | -0.04 | ||
Dahl, 2010 [14] | Indacaterol 300 μg | 52 | 437 | 0.6 | 133 | -- | -- | Inda300 vs. Placebo: 0.16 |
Indacaterol 600 μg | 52 | 428 | 0.57 | 116 | -- | -- | Inda600 vs. Placebo: 0.15 | |
Formoterol | 52 | 435 | 0.56 | 126 | -- | -- | F vs. Placebo: 0.05 | |
Placebo | 52 | 432 | 0.74 | 145 | -- | -- | ||
Donohue, 2014 [24] | UMEC/VI 125/25 mcg | 52 | 226 | -- | 30 | UMEC/VI vs. Placebo: 0.6 | 0.18 | UMEC/VI vs. Placebo: 0.231 |
UMEC 125 mcg | 52 | 227 | -- | 34 | UMEC vs. Placebo: 0.4 | 0.13 | UMEC vs. Placebo: 0.178 | |
Placebo | 52 | 109 | -- | 26 | -- | -0.05 | -- | |
Ferguson, 2008 [17] | Fluticasone propionate/salmeterol (FSC) 250/50 | 52 | 394 | 1.06 | 211 | FP/S vs. S: 0.75 | -0.012 | -- |
Salmeterol 50 μg | 52 | 388 | 1.53 | 230 | -- | -0.082 | -- | |
Kerwin, 2012 [25] | NVA237 50 μg qd | 52 | 529 | 0.54 | NVA vs. Placebo: 0.66 | 0.112 | NVA vs. Placebo: 0.108 | |
Tiotropium 18 μg qd | 52 | 268 | -- | -- | NVA vs. Tio: 1.1 | 0.092 | NVA vs. Tio: 0.019 | |
Placebo | 52 | 269 | 0.8 | -- | -- | -0.097 | ||
Sharafkhaneh, 2012 [26] | Budesonide/formoterol pMDI 160/4.5 μg x 2 inhalations bid (320/9 μg) | 52 | 407 | 0.867 | 169 | -- | 0.07 | -- |
Budesonide/formoterol pMDI 80/4.5 μg x 2 inhalations bid (160/9 μg) | 52 | 408 | 0.952 | 173 | -- | 0.07 | -- | |
Formoterol DPI 4.5 μg x 2 inhalations bid (9 μg) | 52 | 404 | 1.171 | 182 | -- | 0.04 | -- | |
Tang, 2013 [27] | Tiotropium 5 μg (2 x 2.5 μg/puff) | 48 | 167 | -- | 58 | Tio5 vs. Placebo: 0.54 | -- | Tio5 vs. Placebo: 0.134 |
Placebo (2 puffs) | 48 | 171 | -- | 83 | -- | -- | -- | |
Tashkin, 2008 [11] | Tiotropium 18 μg once daily; followed by 40 μg of ipratropium four times daily for 30 days after 4 years of treatment. | 206 | 2987 | -- | 2001 | -- | 0.03 | -- |
Placebo once daily; followed by 40 μg of ipratropium four times daily for 30 days after 4 years of treatment. | 206 | 3006 | -- | 2049 | -- | -0.05 | -- | |
Calverley, 2009 [28] | Roflumilast 500 mcg once per day | 52 | 765 | 1.08 | 344 | ROLF500 vs. Placebo (Trial 1): 0.88 | 0.046 | ROLF500 vs. Placebo (Trial 1): 0.039 |
Placebo | 52 | 758 | 1.27 | 389 | -- | 0.008 | -- | |
Roflumilast 500 mcg once per day | 52 | 772 | 1.21 | 373 | ROLF500 vs. Placebo (Trial 2): 0.89 | 0.033 | ROLF500 vs. Placebo (Trial 2): 0.058 | |
Placebo | 52 | 796 | 1.49 | 432 | -- | -0.025 | -- | |
Dransfield, 2013 [22] | Vilanterol 25 μg | 52 | 409 | 1.05 | -- | FF200 + V vs. V: 0.9 | -0.04 | -- |
Fluticasone furoate 50 μg + Vilanterol 25 μg | 52 | 408 | 0.92 | -- | FF100 + V vs. V: 0.7 | 0 | -- | |
Fluticasone furoate 100 μg + Vilanterol 25 μg | 52 | 403 | 0.7 | -- | FF50 + V vs. V: 0.9 | 0.02 | -- | |
Fluticasone furoate 200 μg + Vilanterol 25 μg | 52 | 402 | 0.9 | -- | -- | 0.02 | -- | |
Vilanterol 25 μg | 52 | 409 | 1.14 | -- | FF200 + V vs. V: 0.7 | -0.02 | -- | |
Fluticasone furoate 50 μg + Vilanterol 25 μg | 52 | 412 | 0.92 | -- | FF100 + V vs. V: 0.8 | 0.02 | -- | |
Fluticasone furoate 100 μg + Vilanterol 25 μg | 52 | 403 | 0.9 | -- | FF50 + V vs. V: 0.9 | 0.01 | -- | |
Fluticasone furoate 200 μg + Vilanterol 25 μg | 52 | 409 | 0.79 | -- | -- | 0.01 | -- | |
Jones, 2011 [29] | Aclidinium 200 μg | 52 | 627 | 167 | Aclid200 vs. Placebo (Trial 1): 0.00 | -0.013 | ||
Placebo | 52 | 216 | 0.46 | 55 | -- | -0.065 | -- | |
Aclidinium 200 μg | 52 | 600 | 199 | -- | -0.009 | -- | ||
Placebo | 52 | 204 | 0.8 | 81 | -- | -0.024 | -- |
St. George’s respiratory questionnaire
Author, year | Treatment | Time point (weeks) | N Randomized | Definition of exacerbation | Annual exacerbation rate (any) | N with any exacerbation | Comparison data for Time to first exacerbation (Hazard ratio) | Mean change in SGRQ Total Score | Comparison data for SGRQ (treatment difference) |
---|---|---|---|---|---|---|---|---|---|
Bateman, 2010 [10] | Tiotropium 5 μg | 48 | 1989 | B+ | 0.69 | 685 | Tio vs. placebo: 0.93 | -4.7 | Tio5 vs. placebo: -2.9 |
Placebo | 48 | 2002 | 0.87 | 842 | -1.8 | -- | |||
Calverley, 2003 [30] | Budesonide/formoterol 320/9 mg (bid) | 52 | 254 | A | 1.38 | -- | B + F vs. B: 0.77 | -- | B + F vs. B: -4.5 |
Budesonide 400 mg (bid) | 52 | 257 | 1.6 | -- | B + F vs. F: 0.71 | -- | B + F vs. F: -3.4 | ||
Formoterol 9 mg (bid) | 52 | 255 | 1.85 | -- | B + F vs. Placebo: 0.72 | -- | B + F vs. Placebo: -7.5 | ||
Placebo | 52 | 256 | 1.8 | -- | -- | -- | -- | ||
Calverley, 2010 [12] | Beclomethasone/formoterol pMDI 400/24 μg | 48 | 237 | NR | 0.414 | 64 | -- | -3.75 | -- |
Budesonide/formoterol DPI 800/24 μg | 48 | 242 | 0.423 | 64 | -- | -4.28 | -- | ||
Formoterol DPI 12 μg | 48 | 239 | 0.431 | 66 | -- | -2.9 | -- | ||
Casaburi, 2002 [31] | Tiotropium 18 μg | 52 | 550 | B | 0.76 | 198 | -- | -3.2 | -- |
Placebo | 52 | 371 | 0.95 | 156 | -- | 0.5 | -- | ||
Chapman, 2011 [13] | Indacaterol, 150 μg | 52 | 420 | A | -- | -- | Ind150 vs. Placebo: 0.82 | -7.5 | -- |
Indacaterol, 300 μg | 52 | 418 | -- | -- | Ind300 vs. Placebo: 0.86 | -5.5 | -- | ||
Placebo | 52 | 425 | -- | -- | -- | -5.5 | -- | ||
Dahl, 2010 [14] | Indacaterol 300 μg | 52 | 437 | A | -- | -- | Inda300 vs. Placebo: 0.77 | -6.5 | Inda300 vs. Placebo: -4.7 |
Indacaterol 600 μg | 52 | 428 | -- | -- | Inda600 vs. Placebo: 0.69 | -7.2 | Inda600 vs. Placebo: -4.6 | ||
Formoterol | 52 | 435 | -- | -- | F vs. Placebo: 0.77 | -7 | F vs. Placebo: -4 | ||
Placebo | 52 | 432 | -- | -- | -- | -1.7 | -- | ||
Decramer, 2013 [15] | Tiotropium bromide 18 μg | 26 | 1721 | C | -- | -- | -- | -5.2 | -- |
Indacaterol maleate 150 μg once-daily | 26 | 1723 | -- | -- | -- | -4.5 | -- | ||
Tiotropium bromide 18 μg | 52 | 1721 | 0.61 | 547 | -- | -4.9 | -- | ||
Indacaterol maleate 150 μg once-daily | 52 | 1723 | 0.79 | 619 | -- | -4.5 | -- | ||
Ferguson, 2008 [17] | Fluticasone propionate/salmeterol (FSC) 250/50 | 52 | 394 | C | 4.82 | 343 | -- | -3.49 | FP/S vs. S: -1.86 |
Salmeterol 50 μg | 52 | 388 | 5.78 | 335 | -- | -1.86 | -- | ||
Vincken, 2002 [19] | Tiotropium 18 μg qd in the morning | 52 | 356 | B | 0.73 | 125 | -- | -3.74 | Tio18 vs. Ipra40: -3.3 |
Ipratropium 40 μg qid | 52 | 179 | 0.96 | 82 | -- | -0.44 | -- | ||
Wedzicha, 2014 [32] | beclomethasone dipropionate/formoterol fumarate (BDP/FOR) 100/6 μg, 2 inhalations BID | 48 | 602 | F | 0.8 | 264 | BDP + F vs. F: 0.8 | -3.55 | BDP/F vs. F: -2.78 |
Formoterol fumarate (FOR) 12 μg, 1 inhalation BID | 48 | 597 | 1.12 | 294 | -- | -0.77 | -- | ||
Wouters, 2005 [20] | Salmeterol/fluticasone (3 month run in period of salmeterol 50 μg and fluticasone 500 μg bid) | 52 | 189 | E | -- | 115 | -- | 2.4 | S/F vs. S: -0.89 |
Salmeterol (3 month run in period of salmeterol 50 μg and fluticasone 500 μg bid) | 52 | 184 | -- | 109 | -- | 3.2 | -- |
Author, Year | Treatment | Time point (weeks) | N Randomized | Annual exacerbation rate (M-S) | N with M-S exacerbation | Comparison data for Time to first exacerbation (Hazard ratio) | Mean change in SGRQ Total Score | Comparison data for SGRQ (treatment difference) |
---|---|---|---|---|---|---|---|---|
Anzueto, 2009 [23] | Fluticasone propionate/salmeterol 250 mcg/50 μg bid | 52 | 394 | 1.1 | 208 | FP250 + S50 vs. S50: 0.73 | 2.49 | FP250 + S50 vs. S50: -0.81 |
Salmeterol 50 μg bid | 52 | 403 | 1.59 | 234 | -- | 3.28 | -- | |
Bateman, 2010 [20] | Tiotropium 5 μg orally inhaled once daily | 48 | 670 | 0.93 | 249 | -- | -5.1 | Tio5 vs. Placebo: -3.5 |
Tiotropium 10 μg orally inhaled once daily | 48 | 667 | 1.02 | 246 | -- | -5.5 | Tio10 vs. Placebo: -3.8 | |
Placebo | 48 | 653 | 1.91 | 288 | -- | -1.6 | -- | |
Dahl, 2010 [14] | Indacaterol 300 μg | 52 | 437 | 0.6 | 133 | -- | -6.5 | Inda300 vs. Placebo: -4.7 |
Indacaterol 600 μg | 52 | 428 | 0.57 | 116 | -- | -7.2 | Inda600 vs. Placebo: -4.6 | |
Formoterol | 52 | 435 | 0.56 | 126 | -- | -7 | F vs. Placebo: -4 | |
Placebo | 52 | 432 | 0.74 | 145 | -- | -1.7 | -- | |
Ferguson, 2008 [17] | Fluticasone propionate/salmeterol (FSC) 250/50 | 52 | 394 | 1.06 | 211 | FP + S vs. S: 0.75 | -3.49 | FP/S vs. S: -1.86 |
Salmeterol 50 μg | 52 | 388 | 1.53 | 230 | -- | -1.86 | -- | |
Hagedorn, 2013 [33] | Salmeterol xinafoate/fluticasone propionate via a single inhaler (SFC) | 52 | 108 | 0.81 | 42 | -- | -1.8 | -- |
Salmeterol xinafoate/fluticasone propionate via separate inhalers (Sal/FP) | 52 | 106 | 0.98 | 44 | -- | -2.6 | -- | |
Kerwin, 2012 [25] | NVA237 50 μg qd | 52 | 529 | 0.54 | -- | NVA vs. Placebo: 0.66 | -- | NVA vs. Placebo: -3.32 |
Tiotropium 18 μg qd | 52 | 268 | -- | NVA vs. Tio: 1.1 | -- | NVA vs. Tio: -0.48 | ||
Placebo | 52 | 269 | 0.8 | -- | -- | -- | -- | |
Sharafkhaneh, 2012 [26] | Budesonide/formoterol pMDI 160/4.5 μg x 2 inhalations bid (320/9 μg) | 52 | 407 | 0.867 | 169 | -- | -7.2 | -- |
Budesonide/formoterol pMDI 80/4.5 μg x 2 inhalations bid (160/9 μg) | 52 | 408 | 0.952 | 173 | -- | -5.5 | -- | |
Formoterol DPI 4.5 μg x 2 inhalations bid (9 μg) | 52 | 404 | 1.171 | 182 | -- | -5.9 | -- | |
Tang, 2013 [27] | Tiotropium 5 μg (2 x 2.5 μg/puff) | 48 | 167 | -- | 58 | Tio5 vs. Placebo: 0.54 | -7.1 | Tio5 vs. Placebo: -3.9 |
Placebo (2 puffs) | 48 | 171 | -- | 83 | -- | -3.3 | -- | |
Tashkin, 2008 [11] | Tiotropium 18 μg once daily; followed by 40 μg of ipratropium four times daily for 30 days after 4 years of treatment. | 206 | 2987 | -- | 2001 | -- | -1.25 | -- |
Placebo once daily; followed by 40 μg of ipratropium four times daily for 30 days after 4 years of treatment. | 206 | 3006 | -- | 2049 | -- | -1.21 | -- | |
Wedzicha, 2008 [34] | Salmeterol 50 μg + fluticasone propionate 500 μg bid | 104 | 658 | -- | 408 | -- | -1.7 | -- |
Tiotropium bromide 18 μg once daily | 104 | 665 | -- | 392 | -- | 0.37 | S + F vs. Tio18: -2.07 | |
Jones, 2011 [29] | Aclidinium 200 μg | 52 | 627 | -- | 167 | Aclid200 vs. Placebo (trial 1): 1.00 | -- | Aclid200 vs. Placebo (trial 1): -1.53 |
Placebo | 52 | 216 | -- | 55 | -- | -- | -- | |
Aclidinium 200 μg | 52 | 600 | -- | 199 | -- | -- | Aclid200 vs. Placebo (trial 2): -2.21 | |
Placebo | 52 | 204 | -- | 81 | -- | -- | -- |